Lord, Abbett & Co
TRIL

Lord, Abbett & Co’s Trillium Therapeutics Inc. TRIL Stock Holding History

Lord, Abbett & Co’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-847,785
Closed -$8.22M – 717
2021
Q2 		$8.22M Sell
847,785
-80,862
-9% -$761K 0.02% 562
2021
Q1 		$9.97M Buy
928,647
+334,135
+56% +$4.13M 0.03% 524
2020
Q4 		$8.74M Buy
594,512
+263,673
+80% +$3.8M 0.02% 546
2020
Q3 		$4.7M Buy
+330,839
New +$3.3M 0.02% 569

Other funds holding TRIL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Lord, Abbett & Co's TRIL Position: Q3 2021 in Review

Lord, Abbett & Co sold out of Trillium Therapeutics Inc. (TRIL) in Q3 2021, closing a stake of 847,785 shares — an estimated $8.22M sold.

Lord, Abbett & Co first reported a position in TRIL in Q3 2020 and held it in 4 quarters. The position peaked at $9.97M in Q1 2021. 181 funds tracked by Wall St. Rank hold TRIL as of Q3 2021.

  • Lord, Abbett & Co reported no remaining Trillium Therapeutics Inc. position as of Q3 2021 after selling out during the quarter.
  • Lord, Abbett & Co sold 847,785 Trillium Therapeutics Inc. shares in Q3 2021, an estimated $8.22M.
  • Lord, Abbett & Co first reported a position in Trillium Therapeutics Inc. in Q3 2020 and held it in 4 quarters.
  • Lord, Abbett & Co's Trillium Therapeutics Inc. position peaked at $9.97M in Q1 2021.
  • 181 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q3 2021.

Based on Lord, Abbett & Co's 13F filing for Q3 2021, filed 9 Nov 2021.